BR112018068347A2 - compostos de cinolin-4-amina e seu uso no tratamento de câncer - Google Patents

compostos de cinolin-4-amina e seu uso no tratamento de câncer

Info

Publication number
BR112018068347A2
BR112018068347A2 BR112018068347A BR112018068347A BR112018068347A2 BR 112018068347 A2 BR112018068347 A2 BR 112018068347A2 BR 112018068347 A BR112018068347 A BR 112018068347A BR 112018068347 A BR112018068347 A BR 112018068347A BR 112018068347 A2 BR112018068347 A2 BR 112018068347A2
Authority
BR
Brazil
Prior art keywords
compounds
salts
formula
report
cinolin
Prior art date
Application number
BR112018068347A
Other languages
English (en)
Inventor
Christophe Barlaam Bernard
Gordon Pike Kurt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112018068347A2 publication Critical patent/BR112018068347A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

este relatório refere-se geralmente a compostos da fórmula (i): (i) e seus sais farmaceuticamente aceitáveis, onde r1, r2 e r3 têm qualquer um dos significados definidos aqui. o relatório refere-se também ao uso de tais compostos e seus sais para tratar ou prevenir doença mediada pela cinase atm, incluindo o câncer. o relatório refere-se adicionalmente a formas cristalinas da fórmula (i) e seus sais farmaceuticamente aceitáveis; composições farmacêuticas compreendendo tais compostos e seus sais; estojos compreendendo tais compostos e seus sais; métodos de preparação de tais compostos e seus sais; intermediários úteis na preparação de tais compostos e seus sais; e com métodos de tratamento de doença mediada pela cinase atm, incluindo o câncer, usando compostos da fórmula (i) e seus sais sozinhos ou em combinação com outras terapias.
BR112018068347A 2016-03-21 2017-03-20 compostos de cinolin-4-amina e seu uso no tratamento de câncer BR112018068347A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662310883P 2016-03-21 2016-03-21
PCT/EP2017/056592 WO2017162605A1 (en) 2016-03-21 2017-03-20 Cinnolin-4-amine compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
BR112018068347A2 true BR112018068347A2 (pt) 2019-01-15

Family

ID=58361025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068347A BR112018068347A2 (pt) 2016-03-21 2017-03-20 compostos de cinolin-4-amina e seu uso no tratamento de câncer

Country Status (18)

Country Link
US (1) US20190099421A1 (pt)
EP (1) EP3433251A1 (pt)
JP (1) JP2019512512A (pt)
KR (1) KR20180127419A (pt)
CN (1) CN108884084A (pt)
AR (1) AR107937A1 (pt)
AU (1) AU2017237394A1 (pt)
BR (1) BR112018068347A2 (pt)
CA (1) CA3017035A1 (pt)
CO (1) CO2018010951A2 (pt)
DO (1) DOP2018000197A (pt)
IL (1) IL261648A (pt)
MA (1) MA43733A (pt)
MX (1) MX2018011283A (pt)
PE (1) PE20181895A1 (pt)
SG (1) SG11201806982PA (pt)
TW (1) TW201808939A (pt)
WO (1) WO2017162605A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111344293A (zh) * 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
CA3093499A1 (en) * 2018-03-14 2019-09-19 Merck Patent Gmbh Compounds and uses thereof to treat tumors in a subject
CN112752758B (zh) * 2018-09-14 2023-05-23 苏州赞荣医药科技有限公司 作为ATM激酶选择性调节剂的咪唑并[4,5-c]噌啉-2-酮化合物及其用途
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CL2008000191A1 (es) * 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
CN103339110A (zh) 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
WO2012162254A1 (en) * 2011-05-23 2012-11-29 Elan Pharmaceuticals, Inc. Inhibitors of lrrk2 kinase activity
NO2714752T3 (pt) * 2014-05-08 2018-04-21

Also Published As

Publication number Publication date
IL261648A (en) 2018-10-31
CA3017035A1 (en) 2017-09-28
US20190099421A1 (en) 2019-04-04
EP3433251A1 (en) 2019-01-30
JP2019512512A (ja) 2019-05-16
TW201808939A (zh) 2018-03-16
WO2017162605A1 (en) 2017-09-28
MA43733A (fr) 2018-11-28
MX2018011283A (es) 2019-05-27
AU2017237394A1 (en) 2018-11-01
SG11201806982PA (en) 2018-09-27
PE20181895A1 (es) 2018-12-11
DOP2018000197A (es) 2018-10-15
AR107937A1 (es) 2018-06-28
CN108884084A (zh) 2018-11-23
CO2018010951A2 (es) 2018-10-22
KR20180127419A (ko) 2018-11-28

Similar Documents

Publication Publication Date Title
BR112018007772A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
BR112018068347A2 (pt) compostos de cinolin-4-amina e seu uso no tratamento de câncer
BR112017028504A2 (pt) derivados de sulfamoilarilamida ciclizada e uso dos mesmos como medicamentos para o tratamento da hepatite b
BR112018007811A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
BR112013032974A2 (pt) &#34;derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas&#34;.
BR112019007393A2 (pt) derivados 6,7,8,9-tetra-hidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento de câncer
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
BR112017009276A8 (pt) Pirazolo[1,5-a]pirimidinas substituídas e seu uso no tratamento de distúrbios médicos
BR112018008397A2 (pt) derivados de di-hidroimidazopirazinona úteis no tratamento do câncer
BR112013005426A2 (pt) &#34;composto, composição, formulação farmacêutica, métodos para inibir uma enzima, para matar e/ou prevenir o crescimento de um micro-organismo, para tratar e/ou prevenir uma doença em um animal, e para inibir o domínio de edição de uma sintetase de t-rna, e, uso de um composto ou uma de combinação.&#34;
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
BR112018070586A2 (pt) compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
BR112015024939A2 (pt) composto, diastereoisômero ou epímero de um composto, composição farmacêutica, uso de um composto, processo para a preparação de um composto, e, método para tratamento de uma infecção
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
BR112017001160A2 (pt) [1,2,4]triazol[4,3-b]piridazinas para uso no tratamento de doenças proliferativas
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
BR112018008330A2 (pt) compostos 1,3,4-tiadiazol e seu uso no tratamento de câncer
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
BR112018068462A2 (pt) composto, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de um composto.
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112017020315A2 (pt) compostos, diastereoisômeros ou epímeros, composição farmacêutica, uso e processo de preparação de compostos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2559 DE 21/01/2020.

B350 Update of information on the portal [chapter 15.35 patent gazette]